Comparative Analysis: YK-11 vs. RAD-140 (Testolone)

Abstract

Selective Androgen Receptor Modulators (SARMs) are a class of therapeutic compounds with similar anabolic properties to anabolic steroids but with reduced androgenic activity. This article compares YK-11 and RAD-140 (Testolone), two of the most potent compounds currently discussed in sports pharmacology and musculoskeletal research. While both target the androgen receptor (AR), they possess distinct chemical structures and biological mechanisms. YK-11 is a steroidal derivative that functions as a partial AR agonist and a myostatin inhibitor via follistatin induction, with data currently limited to in vitro models. RAD-140 is a non-steroidal SARM with high AR affinity, extensive animal data, and emerging Phase I human clinical data. This comparison highlights their disparate mechanisms, efficacy profiles, and the substantial gap in safety data between the two compounds.

---

Mechanism Comparison

YK-11: Myostatin Inhibition and Follistatin Induction

YK-11 is chemically unique among SARMs due to its steroidal backbone, derived from 5α-dihydrotestosterone (DHT). Its primary mechanism of action is twofold:

1. •Partial AR Agonism: It binds to the AR but lacks the full transactivation capacity of testosterone.
2. •Myostatin Antagonism: Its most significant feature is the induction of Follistatin (FST) expression. Follistatin is a glycoprotein that binds to and inhibits myostatin (GDF-8), a TGF-β family member that limits muscle growth. By suppressing myostatin, YK-11 theoretically removes the "genetic ceiling" on muscle hypertrophy (Kanno et al., 2013).

RAD-140 (Testolone): Selective AR Agonism and Neuroprotection

RAD-140 is a non-steroidal SARM designed to overcome the limitations of steroidal compounds (such as liver toxicity and aromatization).

1. •Tissue Selectivity: RAD-140 exhibits high affinity for the AR, showing potent anabolic effects in muscle and bone while maintaining a high degree of selectivity against androgenic tissues like the prostate (Miller et al., 2010).
2. •Neuroprotection: Unlike many SARMs, RAD-140 has demonstrated the ability to cross the blood-brain barrier and exert neuroprotective effects by activating AR-mediated signaling pathways that reduce apoptosis induced by amyloid-beta and excitotoxins (Jayaraman et al., 2014).

---

Efficacy Comparison

| Feature | YK-11 | RAD-140 (Testolone) | | :--- | :--- | :--- | | Primary Goal | Muscle hypertrophy via myostatin inhibition | Selective muscle/bone anabolism | | Evidence Level | In Vitro (Cell culture) | In Vivo (Animal) & Phase I Human | | Anabolic Potency | High (Theoretical) | High (Comparable to Testosterone) | | Neuroprotection | Not observed/studied | Significant (Preclinical models) | | Bone Density | Potential increase (via AR) | Proven increase in animal models |

Efficacy Findings

• •YK-11: In C2C12 myoblast cultures, YK-11 increased the expression of myogenic differentiation markers (MyoD, Myogenin) and proliferating cell nuclear antigen (PCNA). The increase in follistatin was identified as the key driver of these effects (Kanno et al., 2011). However, no studies have yet confirmed these results in living mammals.
• •RAD-140: In orchidectomized rats, RAD-140 demonstrated a dose-dependent increase in levator ani muscle weight with minimal impact on prostate weight at therapeutic doses. In cynomolgus monkeys, it resulted in a mean increase of over 10% in lean body mass over 28 days (Miller et al., 2010). Recent human data in postmenopausal women with breast cancer showed clinical benefit in AR-positive tumors (LoRusso et al., 2022).

---

Safety & Side Effect Comparison

Side Effects of YK-11

Due to the total absence of animal or human trials, the safety profile is purely speculative based on its chemical structure:

• •HPTA Suppression: As a DHT derivative, it likely suppresses endogenous testosterone.
• •Hepatotoxicity: Steroidal compounds with modified structures often pose risks to liver enzymes (ALT/AST).
• •Joint/Tendon Health: Some anecdotal reports suggest joint discomfort, possibly due to low estrogen levels or the intensity of myostatin inhibition, though this is unverified.

Side Effects of RAD-140

RAD-140 has more documented safety data:

• •Liver Enzymes: Clinical trials and case reports have noted elevations in liver transaminases (ALT/AST), suggesting potential drug-induced liver injury (DILI) at higher doses (LoRusso et al., 2022; Flores et al., 2020).
• •Lipid Profile: RAD-140 typically reduces HDL (good cholesterol) and increases LDL.
• •Suppression: Significant suppression of total testosterone, LH, and FSH occurs, requiring post-cycle recovery.

---

Pharmacokinetics Comparison

• •YK-11: There is currently no published data regarding the half-life, bioavailability, or metabolism of YK-11 in humans. It is unknown if the compound is orally stable or requires specific delivery methods for efficacy in vivo.
• •RAD-140: In human trials, RAD-140 demonstrated a surprisingly long half-life of approximately 60 hours. This allows for stable blood concentrations with once-daily or even less frequent dosing (LoRusso et al., 2022).

---

Research Limitations

The comparison between these two compounds is heavily skewed by the depth of available research:

1. •YK-11: The scientific community’s knowledge of YK-11 is restricted to cell cultures. There is a profound lack of "proof of concept" in animal models, let alone humans. Its status as a SARM is debated; it may be more accurately classified as a synthetic steroid with myostatin-inhibiting properties.
2. •RAD-140: While RAD-140 has entered human clinical trials, these studies focus on oncological applications (breast cancer) rather than performance enhancement or muscle wasting in healthy populations. Long-term safety data (beyond 12 months) is non-existent.

---

References

1. •Kanno, Y., et al. (2011). "(17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor." Biological and Pharmaceutical Bulletin, 34(3), 318-323. DOI: 10.1248/bpb.34.318
2. •Kanno, Y., et al. (2013). "Selective androgen receptor modulator, YK11, up-regulates proliferating cell nuclear antigen (PCNA) and myogenic differentiation factor (MyoD) in C2C12 myoblasts." Biological and Pharmaceutical Bulletin, 36(9), 1460-1465. DOI: 10.1248/bpb.b13-00231
3. •Miller, C. P., et al. (2010). "Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140." ACS Medicinal Chemistry Letters, 1(9), 526-530. DOI: 10.1021/ml1000357
4. •Jayaraman, A., et al. (2014). "The SARM RAD140 is neuroprotective in cultured neurons and kainate-lesioned rats." Endocrinology, 155(4), 1398-1406. DOI: 10.1210/en.2013-1725
5. •LoRusso, P., et al. (2022). "Phase I Study of RAD140 in Postmenopausal Women with ER+/HER2- Metastatic Breast Cancer." Clinical Cancer Research, 28(5), 858-870. DOI: 10.1158/1078-0432.CCR-21-2405
6. •Flores, J. E., et al. (2020). "Drug-Induced Liver Injury by Selective Androgen Receptor Modulators." Hepatology Communications, 4(3), 450-452. DOI: 10.1002/hep4.1456